STOCK TITAN

Syneos Health Adds HUB Patient Suite to Deployment Solutions Business

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary

Syneos Health (Nasdaq:SYNH) has launched a dedicated HUB Patient Suite aimed at optimizing prescription management and improving patient adherence. This solution integrates advisory, analytics, and digital capabilities to enhance the patient experience from prescription to therapy adherence. With a focus on data-driven decision-making, the HUB will streamline communications between patients, providers, and biopharma companies. The initiative includes an exclusive partnership with Phil Inc. to modernize patient access to medications, ensuring patients receive necessary therapies effectively.

Positive
  • Introduction of HUB Patient Suite to enhance patient experience.
  • Integration of consulting, communications, and reimbursement services.
  • Partnership with Phil Inc. to improve access to prescriptions.
Negative
  • None.

Brings Together the Industry’s Most Comprehensive Suite of Modular Patient Services, Optimizing Patient Experience from Prescription to Adherence

MORRISVILLE, N.C., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it is introducing a dedicated HUB Patient Suite combining the Company’s advisory, analytics and digitally-enabled capabilities to bring modern, prescription management services to Syneos Health Deployment Solutions customers.

New HUB Patient Suite services will enhance and connect Syneos Health’s consulting, communications, REMS, Field Reimbursement and Nurse Educator expertise to help customers remove patient access barriers and improve medication adherence. These solutions are part of the Company’s comprehensive product development model spanning clinical development to Medical Affairs to commercial offerings.

The Syneos Health HUB Patient Suite will further enable customers to make data-driven decisions by putting the patient at the center of prescription management. The solution will serve as a single point of contact for patients, healthcare providers and biopharma customers, streamlining access to medications and delivering comprehensive services to ensure patients seamlessly start and adhere to therapies. Enabled by digital technology, customers will now be able to engage patients through all channels seamlessly – from engagement centers and nurse navigators to high-touch digital platforms.

“Our comprehensive commercial offerings enable biopharmaceutical customers to leverage our experience, insights and global infrastructure to scale-up, reduce risk and accelerate the path to full market potential,” said Deanne Melloy, Chief Commercial Officer, Deployment Solutions, Syneos Health. “Offering customers a HUB Patient Suite complements our insights-enabled product development model, further integrating our customers’ commercial needs. This solution reinforces our Vision – Shortening the Distance from Lab to Life®.”

As part of the new HUB solution, Syneos Health has entered into an exclusive partnership with Phil Inc., a patient access platform company that provides technology to improve access for patients to their prescriptions. Partnering with Phil, Inc. will transform the patient experience for prescription management from prescription access to adherence, meeting Syneos Health customers no matter where they are on their product development journey.

“We’re honored to partner with Syneos Health to modernize patient access to prescriptions with a solution that addresses the pain points of patients, providers, insurers and biopharma companies,” said Deepak Thomas, founder and chief executive officer at Phil, Inc. “Our combined solution provides hands-on, high touch service, aided by the best Silicon Valley technology and tools, to remove friction from every step of the prescription process. By removing barriers to accessing medication, we can help patients receive and adhere to the prescriptions they need and create exponentially better health outcomes.”

About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically integrating clinical development, medical affairs and commercial capabilities to address modern market realities.

We bring together more than 29,000 minds, across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.

To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.

Investor Relations Contact: Press/Media Contact:
Ronnie SpeightGary Gatyas
Senior Vice President, Investor RelationsExecutive Director, External Communications
+1 919 745 2745+1 908 763 3428
Investor.Relations@syneoshealth.comgary.gatyas@syneoshealth.com


FAQ

What is the new HUB Patient Suite by Syneos Health?

The HUB Patient Suite is a new service designed to improve patient adherence and streamline prescription management by integrating various capabilities and services.

How does the HUB Patient Suite benefit patients and providers?

It connects patients, healthcare providers, and biopharma clients, enabling seamless access to medications and enhancing overall patient experience.

What partnership did Syneos Health announce in the press release?

Syneos Health announced an exclusive partnership with Phil Inc. to modernize patient access to prescriptions and improve adherence.

When was the HUB Patient Suite launched?

The HUB Patient Suite was announced on October 27, 2022.

What is Syneos Health's stock symbol?

Syneos Health is traded under the stock symbol 'SYNH' on Nasdaq.

Syneos Health, Inc.

NASDAQ:SYNH

SYNH Rankings

SYNH Latest News

SYNH Stock Data

4.46B
103.15M
0.49%
94.75%
6.52%
Diagnostics & Research
Healthcare
Link
United States
Morrisville